Published since 1965, Laser Focus World provides comprehensive global coverage of optics, photonics, and optoelectronic technologies, applications, and markets. With 80,000+ qualified print subscribers and over a half-million annual visitors to our online content, we are the go-to source to access decision makers and stay in-the-know.

In addition to providing in-depth articles written by Laser Focus World editors, Laser Focus World accepts articles, news stories, and new product information for publication from qualified outside contributors. 

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Subscribe

A Laser Focus World newsletter subscription is free to qualified professionals. Subscribe here.

Get Published!

Laser Focus World welcomes original, bylined contributed articles for publishing, provided the material is non-commercial and runs first on our site. For consideration, contact Sally Cole Johnson ([email protected]). For more information, see our Editorial Guidelines

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics. Watch here.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community. Listen here.

Contact Us

Newsletter Archive

Magazine Archive

Meet the Laser Focus World Team

Editorial

Contact Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.

The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.

Media Contact: 
Jenna Urban 
jurban@cglife.com

Investor Contact: 
Laurence Watts 
619-916-7620 
laurence@newstreetir.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.